Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. (Q40476915)

20 September 2017

Enhanced multiepitope-based vaccines elicit CD8+ cytotoxic T cells against both immunodominant and cryptic epitopes. (English)

1 reference

20 September 2017

John A Tine

1

1 reference

20 September 2017

Huseyin Firat

2

1 reference

20 September 2017

Anne Payne

3

1 reference

20 September 2017

Guy Russo

4

1 reference

20 September 2017

Stephen W Davis

5

1 reference

20 September 2017

Jim Tartaglia

6

1 reference

20 September 2017

François A Lemonnier

7

1 reference

20 September 2017

Pierre Langlade Demoyen

8

1 reference

20 September 2017

Philippe Moingeon

9

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 January 2005

1 reference

20 September 2017

7

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

20 September 2017

23

1 reference

20 September 2017

8

1 reference

20 September 2017

1085-1091

1 reference

Fully mobilizing host defense: building better vaccines

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Strategies for designing vaccines eliciting Th1 responses in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Specificity of the proteasome and the TAP transporter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Design and evaluation of antigen-specific vaccination strategies against cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Melanoma vaccines: prim and proper presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Recombinant viruses as a tool for therapeutic vaccination against human cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Therapeutic vaccines against melanoma and colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from beta2 microglobulin (beta2m) HLA-A2.1 monochain transgenic H-2Db beta2m double knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

H-2 class I knockout, HLA-A2.1-transgenic mice: a versatile animal model for preclinical evaluation of antitumor immunotherapeutic strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

Modulation of the immunogenicity of antigenic determinants by their flanking residues.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

A Single Residue Exchange Within a Viral CTL Epitope Alters Proteasome-Mediated Degradation Resulting in Lack of Antigen Presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

A multivalent minigene vaccine, containing B-cell, cytotoxic T-lymphocyte, and Th epitopes from several microbes, induces appropriate responses in vivo and confers protection against more than one pathogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.01.001

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2003.01.001

1 reference

20 September 2017

1 reference